Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
Sign Up to like & getrecommendations! Published in 2021 at "Digestive and Liver Disease"
DOI: 10.1016/j.dld.2020.12.120
Abstract: Background Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated… read more here.
Keywords: biologic drugs; disease; treated biologic; prevalence sars ... See more keywords